ABEO — Abeona Therapeutics Share News
0.000.00%
Last trade - 00:00- $260.76m
- $128.92m
- $5.82m
Abeona rises on plans to submit marketing application for skin disease therapy
Brief: Abeona Therapeutics Announces Positive Pre-BLA Meeting With FDA For Eb-101 And Plans For BLA Submission
Abeona Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Abeona Therapeutics Reports Second Quarter 2023 Financial Results
Brief: Abeona Therapeutics Inc. Q2 Net Income USD -16.654 Mln
Abeona Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Abeona Therapeutics Announces Submission Of Briefing Package For Pre-BLA Meeting
Brief: Abeona Therapeutics Announces Closing Of $25 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Adage Capital Partners Reports 15.32% Passive Stake In Abeona Therapeutics As Of July 3 - SEC Filing
U.S. RESEARCH ROUNDUP- Galecto, Palo Alto Networks, Zscaler
Brief: Abeona Therapeutics Announces Regulatory Update On Biologics License Application For EB-101
Brief: Abeona Therapeutics Files Prospectus Supplement For Offering Of Up To $106 Mln Shares
Brief: Abeona Therapeutics Announces Additional Phase 3 Viital Study Results For Eb-101 Presented At The International Societies For Investigative Dermatology 2023 Meeting
Brief: Abeona Therapeutics Reports Q1 2023 Financial Results
Abeona Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Abeona Therapeutics Inc Says On March 23, Board Approved Decrease In Size Of Board By 2 Directors, From 9 To 7
Abeona Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Abeona Therapeutics Reports Full Year 2022 Financial Results And Provides Corporate Update
Abeona Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview